PHIO

Phio Pharmaceuticals Corp

Halal Rating :
Comfortable
Last Price $1.3
Market Cap $5.88m
1D Change

-2.33 %

1 Year Change

65.53 %

Next Earnings Date

Yet to be announced

Company Overview

Phio Pharmaceuticals Corp is a biotechnology company developing novel therapeutic treatments using its proprietary self-delivering RNAi (INTASYLâ„¢) therapeutic platform. The company focuses on immuno-oncology, targeting tumor cells and various cells of the immune system to improve the efficacy of immunotherapy treatments.

The company is currently in the development phase and does not generate revenue from its products, as they are still in various clinical trial stages. Their primary focus is on advancing their pipeline of therapeutic candidates through research and development.

Revenue Sources

Pass

As Phio Pharmaceuticals is still in the research and development phase with no commercial products and zero revenue, this criterion is not applicable at this time. The company's planned products and services are focused on medical treatments, which are considered halal.

Reliance on Interest

Reporting Date Total Revenue Total Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Dec. 31, 2024 $6,000 $1.67m - - 0.00% 0.00%

Based on the financial data from the last four quarters, Phio Pharmaceuticals shows zero interest income and zero interest expense. As the company is pre-revenue and still in R&D phase, this criterion is not applicable at this stage of the company's development.

Operational Ethics

Pass

After reviewing available company information, SEC filings, and public records, there is no evidence of any significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.

Rating Justification

Member Vote

Agree: 0 Disagree: 0

Login to vote on this

Comments

Recent News & Updates